Zoetis Inc. (NYSE:ZTS) Shares Sold by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC decreased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 241,863 shares of the company’s stock after selling 6,033 shares during the quarter. Chevy Chase Trust Holdings LLC owned about 0.05% of Zoetis worth $39,407,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of ZTS. Mizuho Securities USA LLC increased its stake in Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after purchasing an additional 4,829,815 shares in the last quarter. International Assets Investment Management LLC increased its stake in Zoetis by 41,235.7% during the 3rd quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock valued at $183,652,000 after purchasing an additional 937,700 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Zoetis by 296.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock valued at $144,917,000 after purchasing an additional 665,331 shares in the last quarter. Nordea Investment Management AB increased its stake in Zoetis by 38.3% during the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock valued at $336,266,000 after purchasing an additional 572,511 shares in the last quarter. Finally, Holocene Advisors LP acquired a new stake in shares of Zoetis in the third quarter worth $110,809,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS opened at $157.54 on Friday. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The company has a market cap of $71.08 billion, a price-to-earnings ratio of 29.61, a PEG ratio of 2.77 and a beta of 0.90. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The firm’s fifty day simple moving average is $168.89 and its two-hundred day simple moving average is $178.98.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Equities analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.27%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is 37.59%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ZTS. Stifel Nicolaus cut their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. UBS Group began coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Barclays increased their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday. Leerink Partners began coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. Finally, Piper Sandler cut their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $214.90.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.